leisure time -WSS

leisure time

author：comprehensive 2025-09-06 06:16:32 - browse：6946

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Washington mulls new rules to avert another Change Healthcare

WSS

Generative AI mines health records to identify patients’ social needs

Abortion pill Supreme Court ruling could impact entire drug industry

The Readout: Lenmeldy, GLP

The SUPPORT Act is critical to fighting the opioid crisis

Abortion pill case raises question: who can sue the FDA?

New menopause drug shows promise in relief for hot flashes

entertainment

leisure time

focus

New air purifier tech could be key to improving indoor air quality

Why the world’s most expensive drug might be worth the price

Supreme Court strikes down use of affirmative action

Health and fitness trackers are measuring the wrong things

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

GSK to buy asthma

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

focus

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Oprah kicked off a national conversation on obesity. Let's have it

There's no autism epidemic. It's an autism diagnosis epidemic

Idaho abortion case may prompt more restrictions in other states

Abortion pill case raises question: who can sue the FDA?

hotspot

hotspot

focus

leisure time